For broader research context on nootropic compounds, including comparative stacks, cycling considerations, and interaction notes, see the Complete Nootropic Cheat Sheet.
What Is Alpha-GPC?
Alpha-GPC, short for alpha-glycerylphosphorylcholine, is a water-soluble choline-containing compound found in small amounts in human tissues and formed during the metabolism of phosphatidylcholine, a major membrane phospholipid. It is also known as choline alfoscerate, L-alpha glycerylphosphorylcholine, or simply alpha GPC. Unlike phosphatidylcholine, which is a larger membrane component, alpha-GPC is a relatively small intermediate that can cross the blood-brain barrier and provide choline for neuronal and membrane-related processes. Commercial products are usually supplied as capsules, tablets, powders, or liquid preparations, with the amount of alpha-GPC commonly stated as the active compound rather than as elemental choline.
The principal reason alpha-GPC attracts interest is its relationship to acetylcholine, a neurotransmitter involved in attention, learning, memory, arousal, and neuromuscular signaling. Alpha-GPC has been investigated as a cognitive-support compound in people with dementia or vascular cognitive impairment and as a performance supplement in healthy adults and athletes. Some clinical studies, particularly older studies involving patients with cognitive disorders, reported symptomatic improvement, while evidence in healthy people is less consistent. Alpha-GPC should therefore be regarded as a research-supported choline donor with potential effects on cholinergic function, not as a proven treatment for dementia, a guaranteed nootropic, or a substitute for medical care.
Quick Reference
Member reference tables summarize the compound's research parameters.
Research Indications
Research Protocols
As reported in cited literature and research-community logs (see Research Citations below), not a personal dosing recommendation.
This member section describes parameters reported in the research literature.
Peptide Interactions
This member section summarizes reported compound interactions and evidence limitations.
Reported Research Time Points
This member section summarizes reported research time points.
Safety Notes
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
This member section discusses research safety considerations and uncertainties.
Quality Indicators
Research Citations
- Cognitive improvement in mild to moderate Alzheimer's dementia after treatment with the acetylcholine precursor choline alphoscerate: a multicenter, double-blind, randomized, placebo-controlled trial
De Jesus Moreno Moreno, M., 2003, Clinical Therapeutics - Choline alphoscerate in cognitive decline and in acute cerebrovascular disease: an analysis of published clinical data
Parnetti, L., Amenta, F., Gallai, V., et al., 2001, Mechanisms of Ageing and Development - Choline: an essential nutrient for public health
Zeisel, S. H., da Costa, K. A., 2009, Nutrition Reviews - An overview of evidence for a causal relationship between dietary availability of choline during development and cognitive function in offspring
McCann, J. C., Hudes, M., Ames, B. N., 2006, Neuroscience and Biobehavioral Reviews